Xiaobin Wu Sells 500 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 500 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $200.00, for a total transaction of $100,000.00. Following the transaction, the chief operating officer now directly owns 4,500 shares in the company, valued at approximately $900,000. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, September 19th, Xiaobin Wu sold 4,500 shares of BeiGene stock. The stock was sold at an average price of $200.14, for a total value of $900,630.00.
• On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40.
• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The shares were sold at an average price of $159.79, for a total value of $233,133.61.

BeiGene Stock Up 1.7 %

NASDAQ:BGNE opened at $201.99 on Friday. The business’s fifty day moving average price is $182.24 and its 200 day moving average price is $164.45. The firm has a market capitalization of $19.57 billion, a price-to-earnings ratio of -26.68 and a beta of 0.61. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a 1-year low of $126.97 and a 1-year high of $215.00.

BeiGene (NASDAQ:BGNE) last issued its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.27) by $1.12. The company had revenue of $929.20 million for the quarter, compared to the consensus estimate of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The firm’s quarterly revenue was up 56.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.64) EPS. On average, sell-side analysts forecast that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on BGNE. Citigroup upped their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. raised their target price on shares of BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. JMP Securities assumed coverage on shares of BeiGene in a research report on Wednesday. They issued a “market outperform” rating and a $288.00 price target on the stock. Finally, Bank of America cut their price objective on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research report on Tuesday, July 9th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, BeiGene presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.21.

Institutional Investors Weigh In On BeiGene

Institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC acquired a new position in shares of BeiGene in the first quarter worth $50,000. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of BeiGene by 51.5% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock valued at $128,000 after buying an additional 279 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of BeiGene in the 4th quarter valued at approximately $183,000. Acadian Asset Management LLC increased its holdings in BeiGene by 204.1% in the first quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after buying an additional 849 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. bought a new position in BeiGene during the first quarter valued at approximately $209,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.